Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.39 |
| ▸ | BRD2 | P25440 | 16/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 16/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 10/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900231 | 0.87 | BRD4 (0.46) | BRD4BRD2BRD3CREBBPQPCT | |
| SCHEMBL22900536 | 0.86 | BRD4 (0.40) | BRD4BRD2BRD3CREBBPQPCT | |
| SCHEMBL22900540 | 0.82 | BRD4 (0.42) | BRD4BRD2BRD3CREBBPQPCT | |
| SCHEMBL22900336 | 0.81 | BRD4 (0.38) | BRD4BRD2BRD3CREBBPQPCT | |
| SCHEMBL22900428 | 0.76 | QPCT (0.40) | BRD4BRD2BRD3CREBBPQPCT | |
| SCHEMBL22900331 | 0.75 | BRD4 (0.37) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL22900277 | 0.75 | BRD4 (0.37) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL22900230 | 0.71 | QPCT (0.37) | BRD4BRD2BRD3CREBBPQPCT | |
| SCHEMBL22900330 | 0.71 | BRD4 (0.47) | BRD4BRD2BRD3CREBBPMDM2 | |
| SCHEMBL22900253 | 0.68 | QPCT (0.58) | BRD4BRD2BRD3CREBBPQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |